Reference Library · 62 compounds
Compound profiles.
Every research peptide we cover, graded by evidence base and tagged for UK regulatory status. Filter, sort, compare.
| Compound | Category | Evidence | UK Status | Updated |
|---|---|---|---|---|
| VK2735 A dual GIP/GLP-1 receptor agonist in Phase 2 development for obesity and weight management | Fat loss | Moderate | Grey area | 30 Jun 2026 |
| Maridebart Cafraglutide (MariTide) A GLP-1 receptor agonist / GIP receptor antagonist peptide in Phase 2 development for obesity | Fat loss | Moderate | Grey area | 30 Jun 2026 |
| Cagrisema Cagrilintide + semaglutide dual amylin and GLP-1 receptor agonist combination under development by Novo Nordisk for obesity and type 2 diabetes | Fat loss | Moderate | POM | 30 Jun 2026 |
| Amycretin Dual amylin/calcitonin receptor agonist for obesity — early-phase investigational peptide | Fat loss | Limited | Grey area | 30 Jun 2026 |
| Survodutide GLP-1/glucagon dual agonist investigational peptide for MASH and obesity | Metabolic | Moderate | Grey area | 30 Jun 2026 |
| Pemvidutide GLP-1/glucagon dual agonist investigational peptide for MASH and obesity | Metabolic | Moderate | Grey area | 30 Jun 2026 |
| Retatrutide Triple-agonist (GLP-1/GIP/Glucagon) research peptide for obesity and metabolic disease | Metabolic | Moderate | Grey area | 30 Jun 2026 |
| Petrelintide A long-acting amylin analogue in Phase 2 development for obesity | Fat loss | Limited | Grey area | 30 Jun 2026 |
| Ecnoglutide A biased GLP-1 receptor agonist in Phase 3 development for obesity and type 2 diabetes | Fat loss | Moderate | Grey area | 30 Jun 2026 |
| Tirzepatide Dual GLP-1/GIP receptor agonist — up to 22.5% weight loss in Phase 3 and now NICE-approved for obesity on the NHS | Fat loss | Strong | POM | 30 Jun 2026 |
| Semax A synthetic ACTH analogue studied for cognitive enhancement and neuroprotection | Cognitive | Limited | Legal | 30 Jun 2026 |
| Selank A synthetic tuftsin analogue studied for anxiolytic and cognitive effects | Cognitive | Limited | Legal | 30 Jun 2026 |
| Dihexa An angiotensin IV-derived peptide studied for cognitive enhancement and synaptogenesis | Cognitive | Limited | Legal | 30 Jun 2026 |
| Cagrilintide Long-acting amylin analogue in development as CagriSema (with semaglutide) for obesity and type 2 diabetes | Fat loss | Moderate | Grey area | 30 Jun 2026 |
| Orforglipron The first orally available, non-peptide GLP-1 receptor agonist — now FDA-approved for weight management | Fat loss | Strong | POM | 30 Jun 2026 |
| LL-37 Human cathelicidin antimicrobial peptide with broad-spectrum antimicrobial and immunomodulatory properties | Healing | Moderate | Legal | 30 Jun 2026 |
| Semaglutide A long-acting GLP-1 receptor agonist with strong clinical evidence for weight management and metabolic research | Fat loss | Strong | POM | 30 Jun 2026 |
| Thymosin Alpha-1 An immune-modulating peptide with a long clinical history in viral hepatitis and emerging interest in oncology and autoimmune research | Other | Moderate | Grey area | 30 Jun 2026 |
| HGH Fragment 176-191 A modified C-terminal fragment of human growth hormone investigated for selective lipolytic effects without the broader metabolic actions of full-length hGH | Fat loss | Limited | Grey area | 30 Jun 2026 |
| GHRP-2 A synthetic growth hormone secretagogue that stimulates GH release via the ghrelin receptor — used in research to study growth hormone deficiency and body composition | Growth hormone | Moderate | Grey area | 30 Jun 2026 |
| PEG-MGF PEGylated Mechano Growth Factor — a modified splice variant of IGF-1 researched for muscle repair and recovery | Body composition | Limited | Grey area | 30 Jun 2026 |
| Liraglutide GLP-1 receptor agonist: the first daily weight-loss peptide to reach clinical approval | Metabolic | Strong | POM | 30 Jun 2026 |
| GHRP-6 A foundational growth hormone-releasing peptide studied for GH secretion, appetite stimulation, and synergy with GHRH analogues | Growth hormone | Moderate | Grey area | 30 Jun 2026 |
| Hexarelin A potent synthetic growth hormone-releasing peptide (GHRP) studied for its effects on GH secretion, cardiac function, and body composition | Growth hormone | Moderate | Grey area | 30 Jun 2026 |
| Mazdutide Dual GLP-1/glucagon receptor agonist in clinical development for obesity and type 2 diabetes | Fat loss | Moderate | POM | 30 Jun 2026 |
| Tesamorelin Growth hormone-releasing hormone analogue for HIV-associated lipodystrophy | Growth hormone | Strong | POM | 30 Jun 2026 |
| Kisspeptin A neuropeptide governing reproductive hormone signalling, with emerging clinical research in endocrinology | Other | Moderate | Legal | 30 Jun 2026 |
| 5-Amino-1MQ An NNMT inhibitor peptide researched for fat loss and metabolic function | Fat loss | Limited | Legal | 30 Jun 2026 |
| Epitalon Synthetic tetrapeptide studied for telomere lengthening and anti-ageing effects | Longevity | Limited | Legal | 30 Jun 2026 |
| Sermorelin Growth hormone-releasing hormone (GHRH) analog used in research to stimulate endogenous GH production | Growth hormone | Moderate | Legal | 30 Jun 2026 |
| Elamipretide (SS-31) A mitochondria-targeted peptide under investigation for primary mitochondrial myopathy, Barth syndrome, and cardiorenal disease | Longevity | Moderate | Grey area | 30 Jun 2026 |
| Melanotan II Melanocortin receptor agonist researched for tanning and sexual function effects | Skin & hair | Moderate | Grey area | 29 Jun 2026 |
| AOD-9604 Modified hGH fragment peptide researched for targeted fat metabolism | Fat loss | Moderate | Legal | 29 Jun 2026 |
| GHK-Cu Copper peptide for skin repair, wound healing, and tissue regeneration research | Healing | Moderate | Legal | 29 Jun 2026 |
| CJC-1295 Long-acting GHRH analogue studied for sustained growth hormone elevation | Growth hormone | Moderate | Legal | 29 Jun 2026 |
| Ipamorelin Selective growth hormone secretagogue studied for GH release, body composition, and recovery | Growth hormone | Limited | Legal | 29 Jun 2026 |
| TB-500 Synthetic thymosin beta-4 fragment studied for tissue repair, wound healing, and anti-inflammatory effects | Healing | Limited | Legal | 29 Jun 2026 |
| MOTS-c Mitochondrial-derived peptide for metabolic regulation, exercise capacity, and insulin sensitivity — a research overview | Metabolic | Limited | Legal | 26 Jun 2026 |
| BPC-157 A synthetic gastric peptide studied for tissue repair in animal models — research use only. | Healing | Limited | Grey area | 26 Jun 2026 |